X0206 3 2018-09-13 0 0001510487 Principia Biopharma Inc. PRNB 0001524064 Sofinnova Venture Partners VIII, L.P. SOFINNOVA VENTURES 3000 SAND HILL ROAD, 4-250 MENLO PARK CA 94025 0 0 1 0 0001559565 Sofinnova Management VIII, L.L.C. SOFINNOVA VENTURES 3000 SAND HILL ROAD, 4-250 MENLO PARK CA 94025 0 0 1 0 0001245624 HEALY JAMES SOFINNOVA VENTURES 3000 SAND HILL ROAD, 4-250 MENLO PARK CA 94025 0 0 1 0 0001202793 POWELL MICHAEL SOFINNOVA VENTURES 3000 SAND HILL ROAD, 4-250 MENLO PARK CA 94025 0 0 1 0 0001590102 Mehra Anand SOFINNOVA VENTURES 3000 SAND HILL ROAD, 4-250 MENLO PARK CA 94025 0 0 1 0 Series B-1 Preferred Stock Common Stock 625482 D Series B-2 Preferred Stock Common Stock 521235 D Series B-3 Preferred Stock Common Stock 453954 D Series C Preferred Stock Common Stock 167537 D Warrant to Purchase Series B-3 Preferred Stock 8.9931 2022-12-29 Series B-3 Preferred Stock 20938 D Each share of the Series B-1 Preferred Stock is convertible, at any time, at the holder's election, into 1 share of the Issuer's common stock. In addition, effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of Series B-1 Preferred Stock will automatically convert into 1 share of the Issuer's common stock. The Series B-1 Preferred Stock has no expiration date. The shares are held of record by Sofinnova Venture Partners VIII, L.P. ("SVP VIII"). Sofinnova Management VIII, L.L.C. ("SM VIII") is the general partner of SVP VIII. The individual managing members of SM VIII are Michael Powell, James Healy and Anand Mehra, and they may be deemed to share voting and dispositive power over the shares held by SVP VIII. Such persons and entities disclaim beneficial ownership over the shares held by SVP VIII except to the extent of any pecuniary interest therein. Each share of the Series B-2 Preferred Stock is convertible, at any time, at the holder's election, into 1 share of the Issuer's common stock. In addition, effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of Series B-2 Preferred Stock will automatically convert into 1 share of the Issuer's common stock. The Series B-2 Preferred Stock has no expiration date. Each share of the Series B-3 Preferred Stock is convertible, at any time, at the holder's election, into 1 share of the Issuer's common stock. In addition, effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of Series B-3 Preferred Stock will automatically convert into 1 share of the Issuer's common stock. The Series B-3 Preferred Stock has no expiration date. Each share of the Series C Preferred Stock is convertible, at any time, at the holder's election, into 1 share of the Issuer's common stock. In addition, effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of Series C Preferred Stock will automatically convert into 1 share of the Issuer's common stock. The Series C Preferred Stock has no expiration date. This warrant is exercisable at any time. /s/ Nathalie Auber, Attorney-in-Fact for Sofinnova Venture Partners VIII, L.P. 2018-09-13 /s/ Nathalie Auber, Attorney-in-Fact for Sofinnova Management VIII, L.L.C. 2018-09-13 /s/ Nathalie Auber, Attorney-in-Fact for James Healy 2018-09-13 /s/ Nathalie Auber, Attorney-in-Fact for Michael Powell 2018-09-13 /s/ Nathalie Auber, Attorney-in-Fact for Anand Mehra 2018-09-13